E-LEARNING
The idea that eLearning can only be used in straightforward applications such as workplace health and safety training is now a thing of the past as health professionals grasp the medium as a way to communicate about more complicated issues, reports Richard Mackillican
communicate with each other. Whether it involves transmitting a breaking new story around the world or just a ‘tweet’ sent between friends, technology has made it quicker and easier than ever before to exchange information.
It is therefore easy to see why eLearning has become a popular way to increase staff skills throughout the NHS, given its convenience and the environmental benefits of bringing learning to the individual.
Initially, many applications of eLearning centred around quite subject matters such as basic health and safety training but as time has progressed, so has the way it is used.
Now, a group of concerned clinicians is using an eLearning programme to raise awareness of HAE or hereditary angio- oedema, a debilitating and potentially deadly condition with which many patients and doctors are unfamiliar.
Patients with the condition have a defect in a protein in their blood which controls swelling. This means that intermittently, some part or another of their body will swell up. This means that they are either disfigured, disabled or, if it is an internal swelling, the patient will be in considerable pain.
“It can also have a terrible effect on the sufferer’s personal life, especially with regards to having a stable job and a family, because the patient can be at the mercy of their condition,” says
68 nhe
T Spreading the word
echnology has revolutionised the way in which people
Dr Hilary Longhurst, consultant immunologist at Barts and The London NHS Trust.
Along with being a potentially extremely painful condition (it is as severe as a heart attack and child birth) and economic burden, HAE can also be deadly.
“There is a thirty per cent chance of mortality over the lifetime of the patient. Even though the chance of dying because of any individual swelling is tiny, there is a risk that if the swelling occurs in the face or the throat that the patient will asphyxiate.”
All of these factors, coupled with the fact that not that many people – let alone doctors – are aware of the condition drove Dr Longhurst and her colleagues to begin working on a programme to raise awareness of HAE.
“I have a special interest in this condition and a huge cohort of patients who suffer from it and I’ve felt for a long time that they do need active specialist treatment because we know that when we treat the swelling acutely, it will not progress.
“Therefore, I feel that there is a real need to educate doctors who are not aware of the condition because when a patient initially presents with symptoms, they will not appear to be suffering severely.
“Doctors will often wait until the symptoms have become more severe until they actually begin to treat the patient. This means that the patient will have already lost a day or two off work, be in pain or, at the very worst, be at risk of asphyxiating. So I’ve been very keen on educating clinicians on this matter.”
The actual eLearning programme itself has been created by one of the companies which manufacture treatments for HAE.
“We have been very lucky because a number of compounds have recently been licensed to treat this condition. This meant that there was an opportunity to get some sponsorship for an educational programme around HAE. The eLearning programme was simply one of the ways in which we wanted to make people more aware.”
The eLearning programme means that any time a patient presents signs of HAE to Dr Longhurst or one of her colleagues, they or the patient can inform that patient’s GP about the eLearning programme. The GP can then learn more about how to treat their patient’s condition.
Because Dr Longhurst has been involved in the process right from the beginning, it has given her the chance to influence the content of the programme.
“I have always been very keen to ensure that the companies involved in the treatment of HAE should also promote education about the condition. They agreed to this and so we had some meetings around what I’d like to see included, such as sections about pathogenesis, treatment and the practical aspects of the condition, along with some case histories.
“Our objectives are to increase knowledge about HAE itself and also what is needed to enable affected people to lead as normal lives as possible.”
So why use eLearning? Sep/Oct 10
“Well, ideally it could all be done by word of mouth but I am just one person with a very busy job so it is crucial that information is spread in as many ways as possible with eLearning being one of those ways.
“It is also a great way to get information across to people which they can then access at their convenience and as I was involved throughout the production process, I feel that the programme itself really manages to express where we are at with regards to HAE at the moment.”
When producing any type of educational programme there will be challenges and in view of the complex subject matter, those challenges are amplified to some extent.
“There was a lot of work involved in putting this programme together and I think that one of the hardest things was narrowing down which information should be included. That being said, the medical writers who helped me put all of this information together were absolutely phenomenal.
“I could not believe that the writer had no idea what HAE was before he began writing about it for me. I was exceptionally lucky to have been given such great support.
“Getting physicians from other specialities – who had a working knowledge of HAE – involved in the programme was difficult. This was because, although we could find the odd clinician who had treated the condition before, on the whole it was very difficult to find anyone with enough experience of the condition.”
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92